Ototoxic effects of carboplatin in organotypic cultures in chinchillas and rats  by Dalian, Ding et al.
2012 Vol.7 No.2
JOURNAL OF
OTOLOGY BASIC RESEARCH
Abstract
Carboplatin, a second-generation platinum chemotherapeutic drug, is considerably less ototoxic than
cisplatin. While common laboratory species such as mice, guinea pigs and rats are highly resistant to
carboplatin ototoxicity, the chinchilla stands out as highly susceptible. Moreover, carboplatin causes an
unusual gradient of cell death in chinchillas. Moderate doses selectively damage type I spiral ganglion
neurons (SGN) and inner hair cells (IHC) and the lesion tends to be relatively uniform along the length of
the cochlea. Higher doses eventually damage outer hair cells (OHC), but the lesion follows the traditional
gradient in which damage is more severe in the base than the apex. While carboplatin ototoxicity has been
well documented in adult animals in vivo, little is known about its in vitro toxicity. To elucidate the ototoxic
effects of carboplatin in vitro, we prepared cochlear and vestibular organotypic cultures from postnatal day
3 rats and adult chinchillas. Chinchilla cochlear and vestibular cultures were treated with carboplatin
concentrations ranging from 50 µM to 10 mM for 48 h. Consistent with in vivo data, carboplatin selectively
damaged IHC at low concentrations (50-100 µM). Surprisingly, IHC loss decreased at higher doses and
IHC were intact at doses exceeding 500 µM. The mechanisms underlying this nonlinear response are
unclear but could be related to a decrease in carboplatin uptake via active transport mechanisms (e.g.,
copper). Unlike the cochlea, the carboplatin dose-response function increased with dose with the highest
dose destroying all chinchilla vestibular hair cells. Cochlear hair cells and auditory nerve fibers in rat
cochlear organotypic cultures were unaffected by carboplatin concentrations <10 µM; however, the damage
in OHC were more severe than IHC once the dose reached 100 µM. A dose at 500 µM destroyed all the
cochlear hair cells, but hair cell loss decreased at high concentrations and nearly all the cochlear hair cells
were present at the highest dose, 5 mM. Unlike the nonlinear dose-response seen with cochlear hair cells,
rat auditory nerve fiber and spiral ganglion losses increased with doses above 50 µM with the highest dose
destroying virtually all SGN. The remarkable species differences seen in vitro suggest that chinchilla IHC
and type I SGN posse some unique biological mechanism that makes them especially vulnerable to
carboplatin toxicity.
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Introduction
Carboplatin (diammine [1,1 cyclobutane dicarboxylato
(2)-0,0’] platinum) is one of the platinum agents with
enhanced anti-tumor activity and reduced side effects in
comparison with cisplatin [1-6]. As a second-generation
platinum compound, carboplatin expresses its anti-neo-
plastic effect in a similar fashion as cisplatin by forming
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inter/intra-strand DNA cross-links when activated by con-
version into aquated species [7, 8].. For the reason of being
highly efficient in anti-cancer actions and of low toxic
side-effects, carboplatin has been used widely to treat vari-
ous types of solid tumors in humans. The side effects of
carboplatin were similar to all adverse effects of cisplatin,
such as myelosuppression, nephrotoxicity, gastrointestinal
upset, peripheral neurotoxicity, electrolyte disturbance
and hepatotoxicity, as well as ototoxicity.Although the lev-
el of side effects of carboplatin is less severe than that of
cisplatin, however, they have attracted increasing attention
from clinical doctors and research scientists [9-22].
The toxic effects of carboplatin were discussed in clinic
reports in as early as the 80s [23-28]. Since then, the ototox-
icity of carboplatin has been studied in several common
laboratory species, such as rats [29-35]. guinea pigs [6, 30, 36-40],
rabbits [41], monkeys [42], mice [43-48], and zebrafish [49]. The
ototoxic effects of carboplatin have been observed vary
significantly across these species. There is very little evi-
dence of ototoxicity in mice. Guinea pigs are relatively
resistant to carboplatin, but damage can occur when ex-
tremely high doses of carboplatin are given. High doses
of carboplatin can cause high frequency hearing loss and
outer hair cell lesion in guinea pigs and the damage pro-
gresses from the base of the
cochlea to the apex, much like most other ototoxic
drugs, such as aminoglycoside antibiotics, or cisplatin
[50-53]. In laboratory rats, moderate-doses of carboplatin do
not affect the cochlea[54]. However, high doses of carbopl-
atin result in a significant reduction in amplitude of dis-
tortion product otoacoustic emissions (DPOAEs) which
suggests that the severe damage takes place at the outer
hair cells level [34, 55]. In contrast to all the above men-
tioned animals, chinchillas treated with carboplatin devel-
op an unusual hair cell lesion that selectively destroys
the inner hair cells and type I spiral ganglion neurons in
the cochlea [10,56-74]. In the chinchilla vestibular system, the
ototoxic effects of carboplatin has been studied, showing
that Type I hair cells and larger ganglion neurons in the
vestibular system are more susceptible to carboplatin [60, 66,
71, 74, 75]. Although the ototoxic effects of carboplatin have
been well documented in various experimental animal
species, however, the mechanism of carboplatin ototoxic-
ity is not quite clear. Specifically, the different targeting
effects of carboplatin in the cochlea among the chinchil-
la and other species are unknown.
The in vitro ototoxic effects of carboplatin have been
studied in very few species using as cell lines and cochle-
ar cultures [30, 76-78]. According to the very limited discov-
eries from previous studies in the rat cochlear culture sys-
tem, carboplatin absolutely selectively destroys outer
hair cells and spiral ganglion neurons in the postnatal
day 3 rat cochlear explant [76-78]. In contrast, carboplatin
selectively destroys inner hair cells and type I spiral gan-
glion neurons in chinchilla cochlear explants as it does
in vivo, from our preliminary findings reported in an
abstract at the Association for Research in Otolaryngology
annual meeting[77]. To determine if the striking species
differences in carboplatin ototoxicity are due to cellular
intrinsic response, we evaluated dose dependent cell
degeneration using cochlear and vestibular organotypic
cultures treated with various concentrations of carboplatin
from postnatal day 3 rat pups, adult rats, and adult chin-
chillas respectively.
Methods
Cochlear and vestibular organotypic cultures and
carboplatin treatment
The cochlear and vestibular organ culture procedures
are similar to those described previously [50,79-85]. The organ-
otypic cultures of cochlear and vestibular end-organs were
prepared from postnatal day 3 SASCO Sprague-Dawley
rats, adult SASCO Sprague-Dawley rats, and adult chin-
chillas respectively. Experiments were performed accord-
ing to the rules and regulations of the Institutional Animal
Care and Use Committee of the State University of New
York at Buffalo and the National Institutes of Health Guide-
lines for the Care and Use of LaboratoryAnimals.
For culturing cochlear and vestibular explants from
postnatal day 3 rats, a drop of rat tail type I collagen gel
was added in Basal Medium Eagle containing 2% sodi-
um carbonate in a 35 mm culture dish. Type I rat-tail col-
lagen (Collaborative Research, 3.76 mg/ml in 0.02 N ace-
tic acid) was mixed with 10X Basal Medium Eagle
(BME, Sigma) and 2% sodium carbonate at a 9:1:1 ratio.
A 10 µl drop of the collagen solution was placed on the
surface of a 35 mm culture dish and allowed to gel for
approximately 30 min. Afterwards, 1.3 ml of culture me-
dium (0.01 g/ml bovine serum albumin, 1% Serum-Free
Supplement [Sigma I-1884], 2.4% of 20% glucose, 0.2%
penicillin G, 1% BSA, 2 mM glutamine, 95.4% of 1X
BME) was added to the dish to level the apical of the col-
lagen gel. The cochlear basilar membrane including spi-
ral ganglion neurons in Rosenthal's canal and vestibular
end-organs including the maculae of saccule and utricle,
and cristae of ampulla were carefully micro-dissected
out, and positioned on the drop surface of collagen gel
and a flat surface preparation was made by gently press-
ing on the tissue with forceps. Surface tension from the
thin layer of culture medium helped to hold the tissue
against the underlying collagen. The cochlear and vestib-
ular explants were placed in an incubator (Forma Scien-
tific 3029, 37o, 5% CO2) overnight. On the second day,
the serum-free medium was exchanged with new medi-
93
2012 Vol.7 No.2
um that contained a specific concentration of carboplatin
(10 µM, 50 µM, 100 µM, 500 µM, 1000 µM, 5000 µM,
or 10000 µM, Sigma C2538), and incubated for 48 h.
Control samples containing only the serum-free medium,
were run concurrently with the experimental samples.
For culturing cochlear and vestibular explants from
adult rats and chinchillas, the cochlear basilar membrane
and vestibular end-organs including the maculae of sac-
cule and utricle, and crista of ampulla were micro-dis-
sected out and embedded in the fresh-made rat-tail colla-
gen gel. After the collagen solution became the gel, 2 ml
of serum-free culture medium was added to the dish for
overnight incubation (Forma Scientific 3029, 37o, 5%
CO2). The serum-free medium containing a specific con-
centration of carboplatin (50 µM, 100 µM, 500 µM,
1000 µM, 5000 µM, or 10000 µM, Sigma C2538) was
added on the second day for another 48 h incubations.
Histology
At the end of the experiment, the cochlear and vestibular
explants were fixed for 2 h with 4% formalin in 0.1 M phos-
phate buffer (pH 7.4). Specimens from postnatal day 3 rat
pups were double-labeled with a monoclonal antibody
against neurofilament 200 (Sigma N0142, clone N52) to
show the auditory nerve fibers and spiral ganglion neurons
plus phalloidin conjugated Alexa Fluor 488 (Invitrogen
A12379) to label the cuticular plate and stereocilia bundles
of the hair cells. After double labeling, specimens were
rinsed in PBS, and then immersed overnight (4³C) in solu-
tion containing 20 µl of mouse anti-neurofilament 200 anti-
body (Sigma p1951, 1:100) dissolved in a solution contain-
ing 20 µl Triton X-100 (10%), 6 µl normal goat serum, 154
µl of 0.1 M PBS. After rinsing in 0.1 M PBS and immersed
in a solution containing 20 µl of secondary goat an-
ti-mouse IgG TRITC (Sigma T5393, 1:200) mixed in 12 µl
normal goat serum, 40 µl Triton X-100 (10%) and 328 µl
of 0.1 M PBS. Specimens were rinsed three times in PBS,
and then stained with Alexa Fluor 488 conjugated phalloi-
din (1:200) for 30 min. After rinsing with PBS, specimens
were mounted on glass slides as surface preparations in
glycerin. Specimens from adult chinchillas were just
stained with Alexa Fluor 488 conjugated phalloidin or
TRITC-labeled phalloidin (Sigma P1951,1:200) for 30
min, and mounted on glass slides in glycerin. Samples
were examined using a confocal microscope (Zeiss
LSM-510 meta, step size 0.5 µm per slice with appropriate
filters to detect the red fluorescence of TRITC labeled neu-
rofilament 200 in nerve fibers and spiral ganglion neurons
or TRITC labeled phalloidin at F-actin in chinchilla stereo-
cilia (excitation 544 nm, emission 572 nm) and green fluo-
rescence of Alexa 488-labeled phalloidin (excitation 488
nm, emission 520 nm) in the cuticular plate and the stereo-
cilia of the hair cells. Confocal images from multiple lay-
ers were projected onto a single plane using the Zeiss LSM
Image Examiner (version: 4, 0, 0, 91). Confocal images
were further processed using adobe photoshop 5.5 soft-
ware.
Results
Damage in cochlear explants from postnatal day 3
rat pups
In the cochlear explants from postnatal day 3 rat pups,
carboplatin treatment for 48 h at various concentrations
(10 µM, 50 µM, 100 µM, 500 µM, 1000 µM, or 5000 µM)
resulted in two distinct patterns of damage of the cochlear
hair cells and the spiral ganglion neurons (Fig. 1). Cochle-
ar hair cells were heavily labeled with Alexa 488 phalloi-
din (green) and the auditory nerve fibers and spiral gan-
glion neurons were stained with neurofilament 200 anti-
body (red) respectively in normal cochlear explants after
48 h of culturing in standard serum-free medium without
carboplatin (Fig. 1A). After treatment with 50 µM carbo-
platin for the same duration, cochlear hair cells were
intact, while the density of auditory nerve fibers started
to decline (Fig. 1B). When carboplatin concentration
increased to 100 µM, the damage to hair cell and auditory
nerve fibers were more evident (Fig. 1C). Carboplatin
treatment at 500 µM destroyed all hair cells and heavily
damaged auditory nerve fibers and spiral ganglion neurons
(Fig. 1D). It is worthwhile to note that when carboplatin
concentration was increased to 1000 µM, the damage to
cochlear hair cells actually decreased, although degenera-
tion of auditory nerve fibers and spiral ganglion neurons
became worse (Fig. 1E). One interesting phenomenon is
that 5000 µM carboplatin resulted in a complete destruc-
tion to auditory nerve fibers and spiral ganglion neurons,
but most cochlear hair cells survived (Fig. 1F).
Hair cell damage in vestibular explants from postna-
tal day 3 rat pups
The photomicrographs in figure 2 are representatives
of macula of utricle 48 h after culturing with various con-
centrations of carboplatin. Figure 2A shows normal sur-
face structures of vestibular hair cells from a normal, un-
treated macula of utricle. Exposing vestibular explants to
10 µM carboplatin for 48 h resulted in a reduction of
hair cell density (Fig. 2B). When the concentration of
carboplatin increased to 50 µM or 100 µM, most hair
cells were completely destroyed (Fig. 2C, 2D). However,
as can be seen in figure 2E and 2F, the hair cell survival
was distinctly increased when the concentration of carbo-
platin exceeded 500 µM.
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Hair cell damage in cochlear explants from adult
rats
The dose effects of carboplatin on adult rat cochlear
explants were somewhat similar to those on postnatal
day 3 rat pups explants: i.e., low dose carboplatin dam-
aged hair cells while high concentration of carboplatin
did not. In addition, outer hair cells were clearly dam-
aged more than inner hair cells (Fig. 3), consistent with
previous in vivo and in vitro studies in rats [31, 34, 76-78].
Hair cell damage in vastibular explants from adult
rats
A similar destructive trend to vestibular explants from
postnatal day 3 rat pups by carboplatin was found in
adult rat vestibular culture system. Examination of the
vestibular hair cells following 48 h of carboplatin expo-
sure at various concentrations (10 µM, 50 µM, 100 µM,
500 µM, 1000 µM, or 5000 µM) revealed that vestibular
hair cells were destroyed at lower concentrations (10
µM, 50 µM, 100 µM, and 500 µM) (Fig. 4A, 4B, 4C,
and 4D), but remained intact at the higher concentrations
(1000 µM, and 5000 µM) (Fig. 4E, and 4F).
Hair cell damage in cochlear explants from adult
chinchillas
The photomicrograph in Fig. 5A shows the orderly
structure of three rows of outer hair cells and a single
row of inner hair cells in a normal cochlear organotypic
culture from an adult chinchilla. carboplatin treatment at
10 µM for 48 h resulted in the loss of inner hair cells,
while sparing the outer hair cells (Fig. 5B). When the
dose of carboplatin was increased to 50 µM, besides the
IHC loss, most outer hair cells were also destroyed (Fig.
Figure 1. Photomicrographs of representative cochlear organotyp-
ic cultures double labeled with a monoclonal antibody against neu-
rofilament 200 to show the auditory nervous system (red) and
phalloidin to show the stereocilia bundles of the hair cell (green).
(A) A cochlear explant treated with 10 µM carboplatin for 48 h
showing no obvious damage of either hair cells or auditory ner-
vous system. (B) A specimen treated with 50 µM carboplatin
showing substantial damage of auditory nerve fibers. (C) A speci-
men treated with 100 µM carboplatin showing massive loss of
both auditory nerve fibers and cochlear hair cells. (D) A specimen
treated with 500 µM carboplatin showing destruction of most hair
cells and severe damage to the auditory nervous system. (E) Even
greater auditory nervous degeneration after 1000 µM carboplatin
treatment, although with less missing hair cells. (F) Complete de-
struction of auditory nerve fibers and spiral ganglion neurons fol-
lowing 5000 µM carboplatin treatment. Unexpectedly, most co-
chlear hair cells have survived.
Figure 2. Photomicrographs of rat vestibular hair cells in the mac-
ula of utricles labeled with Alexa Fluor 488 conjugated phalloidin.
(A) Untreated vestibular explants after 48 h culturing, showing
well-organized vestibular hair cells as in normal controls. (B) Visi-
ble hair cell loss after treatment with 10 µM carboplatin. (C) Mas-
sive loss of vestibular hair cells after 50 µM carboplatin treat-
ment. (D) Destruction of most vestibular hair cells after treatment
with 100 µM carboplatin. (E) Increased hair cells survival after
culturing with 500 µM carboplatin. (F) Mostly intact hair cells af-
ter 1000 µM carboplatin treatment.
Figure 3. Carboplatin-induced structural damage on the organ of
Corti in adult rat cochlear explants. (A) normal control rat cochle-
ar orgnotypic culture in standard serum-free medium after 48 h
without carboplatin treatment. (B) Rat cochlear explants treated
with 100 µM carboplatin for 48 h. Note massive loss of outer hair
cells, with essentially intact inner hair cells.
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5C). However, exposure to 100 µM carboplatin for 48 h
only destroyed the inner hair cells, but not the outer hair
cells (Fig. 5D). Surprisingly, when the concentration of
carboplatin amounted to over 500 µM, most inner hair
cells and outer hair cells were intact (Fig. 5E, 5F). Se-
vere hair cell loss was detected following 48 h exposure
to 50 µM carboplatin, whereas no striking damage to
hair cells were seen after exposure to 500 µM or higher
concentrations of carboplatin. Figure 6 shows the selec-
tive damage to inner hair cells in chinchilla cochlear ex-
plants, concordant with in vivo observation of carboplat-
in-induced inner hair cell degeneration in chinchillas[12,
56-59, 61-64, 69, 73, 86, 87].
Hair cell damage in vestibular explants from adult
chinchillas
Exposing vestibular explants from adult chinchillas to
carboplatin with various concentrations (10 µM, 50 µM,
100 µM, 500 µM, 1000 µM, or 10000 µM) for 48 h re-
sulted in the destruction of hair cells in macular of utri-
cle in a dose-dependent fashion (Fig. 7). The photomicro-
graph in Figure 7A shows the normal vestibular culture
labeled with Alexa Fluor 488-conjugated phalloidin that
intensely labels actin in the stereocilia and, to a lesser ex-
tent, the cuticular plate of hair cells. As can be seen in
figure 7B and figure 7C, the low doses of carboplatin
used (10 µM and 50 µM) did not cause evident damage
to vestibular hair cells. However, carboplatin at 100 µM
was sufficient to bring about the disarray of stereocilia
bundles on some vestibular hair cells (Fig. 7D). When
the concentration of carboplatin was increased to 500
µM, cilia missing was seen in many vestibular hair cells
leaving remnants of the actin ring surrounding the cuticu-
lar plate (Fig. 7E). Increasing the carboplatin dose to
1000, 5000, or 10000 µM destroyed most vestibular hair
cells (Fig. 7F, 7G, 7H). These results indicate that carbo-
Figure 4. Photomicrographs of rat vestibular hair cells in the macula of utricles labeled with Alexa Fluor 488 conjugated phalloidin. (A)
Most hair cells were visible 48 h after 10 μM carboplatin treatment. (B) Tangling and breaking cilia were detected 48 h post-50 μM carbo-
platin. (C) Visible damage on the cuticular plate of hair cells was found 48 h after 100 μM carboplatin cultures. (D) 50 μM carboplatin
treatment for 48 h resulted in massive destruction of hair cells. (E) Most hair cells were intact 48 h after 1000 μM carboplatin treatment.
Figure 5. Surface preparations showing the dose response of carbo-
platin in cochlear organotypic cultures from adult chinchillas. (A)
All inner and outer hair cells are intact 48 h after culturing with
standard culture medium without carboplatin. (B) Massive inner
hair cell loss after 10 µM carboplatin treatment for 48 h while out-
er hair cells are spared. (C) Destruction of both inner and outer
hair cells after treatment with 50 µM carboplatin for 48 h (D),
Missing inner hair cells with obvious damage in their surrounding
supporting cells after 48 h culturing with 100 µM carboplatin.
However, most outer hair cells have survived. (E) With the concen-
tration of carboplatin increased to 500 µM, most inner and outer
hair cells remain essentially normal. (F) Carboplatin treatment at
1000 µM for 48 h results in no damage in hair cells.
Figure 6. Carboplatin-induced structural damage on the organ of
Corti in chinchilla cochlear explants. (A) Normal cochlear hair
cells after 48 h culturing without carboplatin. (B) Chinchilla co-
chlear explants treated with 100 µM carboplatin for 48 h. Note
many missing inner hair cells, but most outer hair cells remain nor-
mal.
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platin-induced vestibular hair cell degeneration is in a
dose-dependent manner in vestibular culture system
from adult chinchilla.
Discussion
As a second-generation platinum antineoplastic agent,
carboplatin is about the same as cisplatin in biological
effects due to formation of the same interstrand/intra-
strand DNA cross links. Although the incidence of carbo-
platin side effects is reduced, however, the antitumor
potential of carboplatin remains the same as its original
design thanks to technological innovation[2]. Despite that
carboplatin has a lower risk of producing adverse reac-
tions than cisplatin, there has been a growing concern
over its adverse neurotoxic and ototoxic potentials in
recent years[10,14,15]. In different experimental animal spe-
cies, carboplatin has been documented as predominantly
affecting outer hair cells in rats and guinea pigs[34, 37, 89]. In
contrast to the findings in these species, carboplatin-in-
duced selective inner hair cell damage in chinchillas
becomes a unique, species-specific toxicity[56, 59, 61-63, 65-67, 74,
75, 82]. An intriguing question that needs to be addressed is
why the various experimental animal species have differ-
ent responses to carboplatin ototoxicity. There has not
been a definite answer. Generally, different drug-induced
responses in different species are considered to be relat-
ed to either species diversity or the cell difference. To
comprehend if the difference in susceptibility to carbopl-
atin ototoxicity in different species is determined by the
cell itself rather than the systemic drug metabolism in
living animal species, we compared the in vitro carbopla-
tin ototoxic effects between chinchillas and rats. Accord-
ing to the results from inner ear organotypic cultures in
the current study, the species-specific ototoxicity of car-
boplatin is believed to be characterized at the cell level
rather than the systemic metabolism.
The biological activation of carboplatin requires hydra-
tion following cell entry. In order to bind to DNA and to
exert its toxic effects, carboplatin must first enter the
cell. Evidence suggests that platinum agents are mainly
imported by copper transporter importer, Ctr1, and export-
ed from cells or cellular organelles by copper transporter
exporters, ATP7A, and ATP7B[74, 82, 84, 85, 90-93, 102]. Cells have
the potential to adjust the activities of copper transport-
ers properly according to the intracellular and extracellu-
lar copper/platinum concentrations[82, 84, 85, 95-103]. According
to reports in the literature, enhanced extracellular concen-
tration of copper by local application on round window
can result in an intrinsic cytoprotective effect of hair
cells against carboplatin by modulating the activities of
copper transporters[53, 82, 84, 85, 102]. These important findings
suggest that intracellular and extracellular copper/plati-
num is detectable by the cells. Experiments indicate that
the high concentration of copper/platinum can lead to a
reduction of uptake by withdrawing Ctr1 from the mem-
brane into the cytoplasm where Ctr1 is quickly degraded,
and also increased efflux of copper/platinum from cyto-
plasm by ATP7A and ATP7B to reduce the accumulation
of copper/platinum in the cell[53, 82, 84, 85, 102]. The cellular
intrinsic modulation of copper transporters is efficient
for the cytoprotection from platinum injury in vitro, but
may not appear in vivo natively. The cause is that in
vitro concentrations of platinum can be high enough to
alert the cell. However, the in vivo concentration of plati-
num in the inner ear is low due to the block by the barrier
between the bloodstream and organic tissues[52, 102, 104-107].
Therefore, the infiltration of platinum in the inner ear by
systemic absorption may not attain enough concentration
to attract cell’s attention. An interesting phenomenon
discovered is that cochlear and vestibular hair cells from
postnatal day 3 rats and adult rats showed a similar non-
linear response to carboplatin ototoxicity, while the dam-
age to auditory nerve fibers and spiral ganglion neurons
in postnatal day 3 rats was in a linear dose dependent
manner. This is different from neurotoxic effects of cispl-
atin in rat cochlear organotypic cultures[82, 84, 85]. In com-
parison with rat cochlear organotypic cultures, cochlear
hair cells of chinchilla were destroyed by carboplatin on-
ly at low concentrations, which is similar to the response
from in vitro studies in various platinum explants[82-85, 102,
108]. The only difference is that inner hair cells in chinchilla
Figure 7. Photomicrographs showing vestibular organotypic cul-
tures from the middle area of macula of utricle after 48 h treatment
with carboplatin in an adult chinchilla culture system. Hair cells
are labeled with Alexa Fluor 488-phalloidin. Carboplatin concen-
trations are shown in each panel. (A) A normal control showing
normal arrangement of vestibular hair cells. Vestibular culture treat-
ed with carboplatin at a concentration of 10 µM shows no damage
of hair cells (B). However, carboplatin treatment at 50 µM and 100
µM for 48 h results in abnormal arrangement of vestibular hair
cells in the macula of utricle (C, D). Cilia in some vestibular hair
cells missing after 48 h of carboplatin treatment at 500 µM. (E).
Massive damage in the macula of utricle when the concentrations
of carboplatin exceeds 1000 µM (F, G, H).
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are more susceptible to carboplatin, while outer hair
cells in rat are the first victims. The species-specific
mechanism of this phenomenon is unclear, but will need
to be addressed in our future studies. The rat vestibular
hair cells have equal dose-response to carboplatin in that
these cells are destroyed by low concentration of carbopl-
atin treatment, but remain intact at high concentrations.
However, chinchilla vestibular hair cells exhibited a
dose dependent response to carboplatin. The cause of the
differences between rats and chinchillas in responses to
carboplatin ototoxicity in vestibular hair cells is not
known. A protective response may be aroused in rat ves-
tibular hair cells by high concentrations of platinum[82, 85,
102, 105]. In contrast, the vestibular hair cells in chinchilla
do not show this intrinsic resistance to carboplatin for
some unknown reasons[76, 77].
To prevent the ototoxic effects of platinum, many strat-
egies can be considered for inner ear protection. Since
platinum can arouse cellular injury by activation of free
radicals[76, 109-113], many antioxidants have been used for
protection against cisplatin toxicity[112,114-118]. Although
antioxidation can effectively protect the cochlea from
platinum damage, it can also compromise the anti-tumor
activity of platinum when treated systemically[119,120].
Therefore,local antioxidant application may be required
for cochlear protection against platinum ototoxicity [118].
Platinum toxicity specifically causes cell apoptosis.
Therefore, anti-apoptotic agents may also provide protec-
tion against platinum toxicity[82,85,121-139]. In addition, neuro-
trophic factors have also been reported to reverse plati-
num induced cochlear injury[140-142]. Although above men-
tioned strategies have seen variable successes, it has to
be pointed out that the key is the process of cell degener-
ation. When the cell has started the degeneration pro-
cess, treatment effects will vary depending on the degree
of lesions. Therefore, the protective actions by antioxida-
tion or anti-apoptosis agents are limited. The results in
our recent publications and the current study, by modulat-
ing copper transporters, may develop a new strategy
against platinum ototoxicity, which keeps cisplatin out of
the cell by reducing platinum influx and enhancing plati-
num efflux[50, 53, 74, 82-85, 102, 105, 108]. When the platinum is isolat-
ed from the cell while in the process of attack, its follow-
ing toxic effects may be unfulfilled.
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